Our tumor-targeting model leverages pro-inflammatory strategies to drive immune cell activation and evaluate anti-tumor efficacy. This platform enables precise assessment of immune-mediated tumor targeting in a controlled and reproducible setting.

Applications & Readouts

Cancer therapeutics and treatment

› Pro-inflammatory efficacy testing
› CAR-T cell and B-cell therapies
› Adaptation to any tumor type

Mechanism of action (MoA) studies

› Analysis of endothelial activation pathways
› Measurement of adhesion molecules and cytokines
› Identification of pro- or anti- inflammatory effects

Vascular modeling

› Vascular flow: capture, rolling, migration and transmigration
› Migratory competence and tumor homing‍

Assays & Methods

Bio-imaging

› High-resolution imaging by phase contrast microscopy

› Immunohistochemistry: visualisation of cellular morphology, drug-specific effects

› Adjustable time-course measurements

Cell tracking

› MesenCount and MesenTrack AI-based softwares

› Label-free or immunofluorescence imaging
under flow

Flow Cytometry

› Recovery and phenotyping of recruited leukocyte subsets in whole blood models
‍
› Identification of endothelial cell activation markers

› Measurement of cytokines production

Example data

T-cell trafficking- assessment of migratory competence through integrin blockade

Trafficking profiles of T-cells on human umbilical vein endothelial cells (HUVECs) stimulated with TNFα + IFNγ. The number of T-cells captured (step-1), the percentage transmigration (step-2) and the number of transmigrated T-cell (step-3) were monitored over 50 minutes, with individual cells quantified using our AI-based software MesenCount. Treatment with anti-β1 and anti-β2 integrin antibodies (grey) markedly reduces T-cell capture and transmigration compared to the isotype control (blue).

➔

Get in touch to build your model